Cytotoxicity and cellular uptake of doxorubicin and its formamidine derivatives in HL60 sensitive and HL60/MX2 resistant cells

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1429-1434

  Kik, Krzysztof ^a   Wasowska Lukawska, Malgorzata ^b   Oszczapowicz, Irena ^b   Szmigiero, Leszek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

Doxorubicin; Formamidinodoxorubicins; Resistant cells; Topoisomerase ii; Uptake

Indexed keywords

ANTHRACYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; DOXORUBICIN DERIVATIVE; FORMAMIDINE; HEXAMETHYLENEIMINE DERIVATIVE; MORPHOLINE;

ARTICLE; CANCER RESISTANCE; CELL FREE SYSTEM; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG UPTAKE; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

AMIDINES; ANTIBIOTICS, ANTINEOPLASTIC; CELL SURVIVAL; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HL-60 CELLS; HUMANS;

EID: 64949178567     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Minotti G, Menna P, Salvatorelli E, Cairo G and Gianni L: Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229, 2004.
2. Oszczapowicz I, Wasowska M, Oszczapowicz J, Owoc A, Dominiczak E, Wietrzyk J and Opolski A: New derivatives of anthracycline antibiotics, method of synthesis and pharmaceutical agents containing them. Polish Patent Application, pp. 381-387, 2005.
3. Wasowska M, Oszczapowicz I, Wietrzyk J, Opolski A, Madej J, Dzmira S and Oszczapowicz J: Influence of the structure of new anthracyclines antibiotics on their biological properties. Anticancer Res 25: 2043-2048, 2005.
4. Wasowska M, Wietrzyk J, Opolski A, Oszczapowicz J and Oszczapowicz I: Effect of structural modification of anthracyclines on the ability to overcome drug resistance of cancer cells. Anticancer Res 26: 2009-2012, 2006.
5. Wasowska-Lukawska M, Wietrzyk J, Opolski A, Oszczapowicz J and Oszczapowicz I: Biological properties of new derivatives of daunorubicin. In Vivo 21: 413-416, 2007.
6. Boland MP, Fitzgerald KA and O'Neill LAJ: Topoisomerase II is required for mitoxantrone to signal nuclear factor B activation in HL60 cells. J Biol Chem 275: 25231-5238, 2000.
7. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of tetrazolium-based semiautomtic colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942,1987.
8. Riganti C, Miraglia E, Viarisio D, Costamagna C, Pescarmona G, Ghigo D and Bosia A: Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux. Cancer Res 65: 516-525, 2005.
9. Lemke K, Poindessous V, Skladanowski A and Larsen AK: The antitumor triazoloacridone C-1305 is a topoisomerase II poison with unusual properties. Molec Pharmacol 66: 1035-1042,2004.
10. Beck WT, Morgan SE, Mo Y and Bhat UG: Tumor resistance to DNA topoisomerase inhibitors: new developments. Drug Resist Updates 2: 382-389, 1999.
11. Zhou SF: Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotics 38: 802-832,2008.
12. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG and Li Y: Substrates and inhibitors of human multidrug resistance-associated proteins and the implications in drug development. Curr Med Chem 15: 1981-2039, 2008.
13. Ciesielska E, Studzian K, Wasowska M, Oszczapowicz I and Szmigiero L: Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety. Cell Biol Toxicol 21: 139-147, 2005.